IPP Bureau

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

By IPP Bureau - November 03, 2023

This project will aim to develop a next-generation A3 adenosine receptor drug agonists

Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs
Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs

By IPP Bureau - November 03, 2023

Lyka Labs has reported total income of Rs. 28.23 crores during the period ended September 30, 2023

Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr
Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr

By IPP Bureau - November 03, 2023

Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023

Dabur India posts Q2 FY24 consolidated PAT at Rs. 515.05 Cr
Dabur India posts Q2 FY24 consolidated PAT at Rs. 515.05 Cr

By IPP Bureau - November 03, 2023

The company has posted net profit of Rs.978.93 crores for the 6 months period ended September 30, 2023

Lincoln Pharmaceuticals posts Q2 FY24 consolidated PAT at Rs. 27.65 Cr
Lincoln Pharmaceuticals posts Q2 FY24 consolidated PAT at Rs. 27.65 Cr

By IPP Bureau - November 03, 2023

Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023

Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr
Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr

By IPP Bureau - November 03, 2023

Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023

Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr
Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr

By IPP Bureau - November 02, 2023

The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202

Zydus acquires UK based LiqMeds Group
Zydus acquires UK based LiqMeds Group

By IPP Bureau - November 02, 2023

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru
Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru

By IPP Bureau - November 02, 2023

Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India

Sun Pharmaceutical Industries Q2 FY 24 consolidated PAT higher at Rs. 2375.51 Cr
Sun Pharmaceutical Industries Q2 FY 24 consolidated PAT higher at Rs. 2375.51 Cr

By IPP Bureau - November 02, 2023

Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023

NATCO Pharma announces successful completion of USFDA inspection
NATCO Pharma announces successful completion of USFDA inspection

By IPP Bureau - November 02, 2023

NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023

Mankind Pharma Q2 FY24 consolidated PAT higher at Rs. 501.02 Cr
Mankind Pharma Q2 FY24 consolidated PAT higher at Rs. 501.02 Cr

By IPP Bureau - November 01, 2023

Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023

Thyrocare Technologies posts Q2 FY24 consolidated PAT at Rs. 20.34 Cr
Thyrocare Technologies posts Q2 FY24 consolidated PAT at Rs. 20.34 Cr

By IPP Bureau - November 01, 2023

Thyrocare Technologies has reported total income of Rs. 150.17 crores during the period ended September 30, 2023

Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr
Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr

By IPP Bureau - November 01, 2023

Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023

Lupin Mandideep plant gets USFDA green signal
Lupin Mandideep plant gets USFDA green signal

By IPP Bureau - November 01, 2023

The inspection of the facility conducted from August 7 to August 11, 2023

Latest Stories

Interviews

Packaging